Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients

BMC Infectious Diseases

Fengmin Lu¹  Hua Liang²  Zhaojun Duan¹  Jian Gao¹  Tao Shen¹  Lu Long¹ 

[1] Department of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, China;State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, China CDC, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing 100026, China

关键词: Ratio;    HCV/HIV-1;    HCV-RNA;    HCV-coreAg;    Coinfection;    CD4+ T-cell counts;   

Others  :  1122126
DOI  :  10.1186/s12879-014-0577-1

 received in 2014-05-08, accepted in 2014-10-22,  发布年份 2014

【 摘 要 】

Background

The measurement of hepatitis C virus core antigen (HCV-coreAg) has been shown to be an indicator of active HCV infection. The aim of the present study was 1) to investigate the stability and effectiveness of HCV-coreAg and HCV-RNA quantification in HCV infection with or without HIV-1 coinfection, 2) to explore the association between the HCV-coreAg/HCV-RNA (Ag/RNA) ratio and the immune status in chronic HCV/HIV-1-coinfected patients.

Methods

A longitudinal investigation comprised of 227 HCV-monoinfected (n = 129) and HCV/HIV-1-coinfected (n = 98) patients was initiated in August 2009, and 139 (73 with HCV monoinfection and 66 with HCV/HIV-1 coinfection) were followed up in August 2012. Both HCV core antigen and HCV RNA quantification were determined on this cryopreserved plasma. HCV core antigen and HCV RNA quantification were performed subsequently. In addition, an in vitro experiment investigating the possibility of degradation of HCV components (core antigen and RNA) were conducted.

Results

Significant and stable correlations (p < 0.001) were observed both in chronic HCV-monoinfected and HCV/HIV-1-coinfected patients over the 3-year observation. Coinfected patients with immunocompromised condition had a significantly higher (p < 0.05) Ag/RNA ratios than those patients with immunocompetent condition both at two time points (2009 and 2012). Moreover, the Ag/RNA ratios were negatively correlated with CD4+ T-cell counts (p < 0.001). An in vitro experiment investigated the possibility of the slower degradation of HCV particles under HIV-related immunocompromised condition was conducted and the data demonstrated that the Ag/RNA ratios were significantly higher in HIV-1-positive plasma than in healthy plasma (p = 0.005) in this study.

Conclusions

Our longitudinal study indicated that the HCV-coreAg presented comparable dynamics over time as HCV RNA in chronic HCV-infected patients. Meanwhile, the HCV-coreAg/HCV-RNA ratio was closely associated with immune status in HCV/HIV-1-coinfected patients.

【 授权许可】

   
2014 Long et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Williams R: Global challenges in liver disease. Hepatology 2006, 44:521-526.
• [2]Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
• [3]Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Brau N, Hatzakis A, Pol S, Rockstroh J: Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007, 21:1073-1089.
• [4]Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P: Viral hepatitis and HIV co-infection. Antiviral Res 2010, 85:303-315.
• [5]Dou Z, Chen RY, Wang Z, Ji G, Peng G, Qiao X, Fu J, Meng X, Bulterys M, Ma Y, Zhao Y, Wang N, Zhang F: HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985–2008. PLoS One 2010, 5:e13737.
• [6]Wu Z, Liu Z, Detels R: HIV-1 infection in commercial plasma donors in China. Lancet 1995, 346:61-62.
• [7]Ji G, Detels R, Wu Z, Yin Y: Correlates of HIV infection among former blood/plasma donors in rural China. AIDS 2006, 20:585-591.
• [8]Ottiger C, Gygli N, Huber AR: Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol 2013, 58:535-540.
• [9]Shen T, Chen X, Zhang W, Xi Y, Cao G, Zhi Y, Wang S, Xu C, Wei L, Lu F, Zhuang H: A higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patients. PLoS One 2011, 6:e23550.
• [10]NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consens State Sci Statements 2002, 19:1-46.
• [11]Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
• [12]Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM: Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002, 36:211-218.
• [13]Park Y, Lee JH, Kim BS, Kim do Y, Han KH, Kim HS: New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010, 48:2253-2256.
• [14]Loggi E, Cursaro C, Scuteri A, Grandini E, Panno AM, Galli S, Furlini G, Bernardi M, Galli C, Andreone P: Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol 2013, 56:207-211.
• [15]Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C: Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol 2012, 55:17-22.
• [16]Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, Galli S, Terlenghi L, Olivares M, Bagnarelli P, Costantini A, De Conto F, Sainz M, Galli C, Manca N, Landini MP, Dettori G, Chezzi C: Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011, 51:264-269.
• [17]Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL: Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009, 46:210-215.
• [18]Garbuglia AR, Monachetti A, Galli C, Sabatini R, Ferreri ML, Capobianchi MR, Bagnarelli P: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes. BMC Infect Dis 2014, 14:222. BioMed Central Full Text
• [19]Zhang W, Hu D, Xi Y, Zhang M, Duan G: Spread of HIV in one village in central China with a high prevalence rate of blood-borne AIDS. Int J Infect Dis 2006, 10:475-480.
• [20]Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
• [21]Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J: Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 2010, 48:18-21.
• [22]Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN: Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol 2012, 50:1989-1993.
• [23]Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M: Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010, 48:1161-1168.
• [24]Schuttler CG, Thomas C, Discher T, Friese G, Lohmeyer J, Schuster R, Schaefer S, Gerlich WH: Variable ratio of hepatitis C virus RNA to viral core antigen in patient sera. J Clin Microbiol 2004, 42:1977-1981.
• [25]Mederacke I, Potthoff A, Meyer-Olson D, Meier M, Raupach R, Manns MP, Wedemeyer H, Tillmann HL: HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. J Clin Virol 2012, 53:110-115.
• [26]Mussini C, Galli L, Lepri AC, De Luca A, Antinori A, Libertone R, Angarano G, Bonfanti P, Castagna A, D'Arminio Monforte A: Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. J Acquir Immune Defic Syndr 2013, 63:339-345.
• [27]Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT: AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS 2010, 24:1549-1559.
• [28]Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
• [29]Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI, Deeks SG, Douek DC, Brenchley JM: Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009, 199:1177-1185.